Telix Pharmaceuticals Logo
Telix Pharmaceuticals Logo
  • Our Company
    • Our Company
    • Purpose, Mission & Values
    • Board & Management
    • Our Technology
    • Sustainability
  • Our Portfolio
    • Our Portfolio
    • Disease Areas
      • Prostate Cancer
      • Kidney Cancer
      • Brain Cancer
      • Musculo-skeletal cancers
    • Clinical Trials
    • Illuccix® & Gozellix®
    • Pipeline
    • Research & Innovation
  • Investor Centre
  • News & Views
  • Careers
    • Careers
    • Find a job
Header Image Frame Header Image Frame

Home News & Views

News & Views

News & Views

TLX66 Meets Study Objectives in Patients with AL Amyloidosis

Clinical, News,

Telix announces bone marrow conditioning investigational candidate TLX66 has met study objectives, demonstrating the initial safety profile in patients with AL…

Read more

First Patient Dosed in Japanese Prostate Cancer Imaging Study

Clinical, News,

Telix announces the first patient has been dosed in a clinical study in Japan using Telix’s investigational prostate cancer imaging product,…

Read more

Telix Pharmaceuticals and Eckert & Ziegler Sign German Distribution Agreement for Prostate Cancer Imaging

ASX, News,

Telix has entered an exclusive commercial distribution agreement with Eckert & Ziegler for Telix’s prostate cancer imaging product Illuccix® for the German…

Read more

Telix at ANZSNM Annual Scientific Meeting

Events, News,

Telix is pleased to announce our participation in the Australian and New Zealand Society of Nuclear Medicine (ANZSNM) Annual Scientific Meeting to be held 21 – 23 May 2021, live…

Read more

Telix Pharmaceuticals Limited AGM 2021 – Chairman and CEO Addresses

ASX, News,

Telix provides the Chairman’s Address and the CEO’s Presentation to the Annual General Meeting of…

Read more

Telix and Monrol Expand Alliance to Include Lutetium Supply

ASX, News,

Telix announces global clinical supply agreement with Monrol for the supply of no carrier added lutetium-177 for use in Telix’s MTR…

Read more

Telix Commences Phase III Clinical Trial of Prostate Cancer Therapy

Clinical, News,

Telix has been granted HREC approval and received CTN clearance by the TGA to commence a Phase III study of the Company’s prostate cancer therapy candidate TLX591, in patients with advanced…

Read more

Telix Announces Executive Leadership Appointments and Establishment of Asia Pacific Operating Region

ASX, News,

Telix announces several key executive leadership appointments, including the establishment of an Asia-Pacific (APAC) operating region, further continuing the Company’s rapid commercial…

Read more

Telix Pharmaceuticals Appoints Richard Valeix as EMEA President

News,

Telix announces Richard Valeix has joined the Telix executive leadership team in the role of President, Europe, Middle East and Africa…

Read more

Telix Pharmaceuticals and Global Medical Solutions Complete Strategic Manufacturing Agreement

ASX, News,

Telix announces it has completed a strategic manufacturing agreement with Global Medical Solutions to manufacture and supply finished unit doses of MTR products for clinical development…

Read more
1 … 35 36 37 38 39 … 50

Subscribe

* indicates required

By subscribing, you are agreeing to the terms of our Global Privacy Policy and provide consent to receive updates from Telix”

Telix Pharmaceuticals Logo
  • Our Company
  • Contact
  • Our Portfolio
  • Careers
  • Investor Centre
  • News & Views

© Telix Pharmaceuticals Limited. 55 Flemington Road, North Melbourne, VIC 3051, Australia.

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Privacy Policy. Terms of Use. Cookies Policy. Privacy Settings